The Leona M. and Harry B. Helmsley Charitable Trust has awarded a $3.5M research grant to Clatit Health Services to evaluate its AI-driven study on the efficacy of diabetes care.
Through the Clalit's Health Services' Schneider Children's Medical Center of Israel, together with researchers from Europe and the United States, the latest effort will evaluate the efficacy of an updated version of the Advisor Pro Platform, developed by DreaMed Diabetes. In this care platform, DreaMed uses artificial intelligence to provide remote care for patients with type 1 diabetes - the seamless treatment is made possible with a virtual diabetes management services that provides unique recommendations on insulin dosage to meet every patient's specific needs.
RELATED: Prevent Type 2 Diabetes: Studies Reveal The Perfect Diet of Fruits, Vegetables, and Whole Grain
The new Advisor Pro Platform sends its recommendations directly to the user, without the need for a pre-approval from healthcare providers, with the dosage adjusted automatically in real-time. DreaMed's AI-driven platform aims to further empower people suffering from diabetes and allow them to better self-manage their condition and receive personalized and real-time insulin recommendations. This cause will be advanced thanks to the recent Helmsley Trust support.
"For years, people with diabetes using insulin injection therapy have been left behind. Most of the technologies that were developed, have yet to address this large portion of the population." said Moshe Philip, Director of the Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes. "I believe that this project will be the first step towards providing the clinical evidence needed to adopt such AI technologies in our routine care."
DreaMed Diabetes
Founded in 2014, DreaMed Diabetes was the first to commercialize the first artificial pancreas technology first published in the New England Journal of Medicine. In the study, originally published on February 28, 2013, researchers assigned patients to receive the treatment with an artificial pancreas on the first night, and a sensor-augmented insulin pump on the second. It found out that on the nights when patients used the artificial pancreas, researchers established that there were "significantly fewer episode" of nighttime glucose levels compared to the nights when patients used sensor-augmented insulin pumps.
Since then, DreaMed has been focused on the development of decision support tools aimed at supporting diabetes patients. An April 2019 study published in the journal Diabetes, Obesity, & Metabolism evaluated the DreaMed GlucoSitter, DreaMed's MD-Logic closed-loop system, in a 60-hour day and night use trial in comparison with sensor-augmented pump (SAP) therapy.
More recently, a study published in the Journal of Diabetes Science and Technology last October 26, evaluates the DreaMed Advisor Pro Platform - comparing the AI platform's insulin dose adjustments to those made by actual physicians.
About Clalit Health Services' Schneider Children's Medical Center
Schneider Children's Medical Center of Israel, located in the central city of Petah Tikva, is the "only comprehensive, tertiary care hospital of its kind in the region." The medical facility offers the full range of pediatric disciplines to meet a variety of medical needs for children from 0 to 18 years old.
The children's medical center also implements an open-door policy, accepting admission from all chlidren, regardless of race, religion, or nationality. Schneider Children regularly offer treatment for children from its neighboring countries.
